Nattokinase
Nattokinase is a potent serine protease enzyme extracted from natto, a traditional Japanese fermented soybean dish. It functions as a powerful systemic fibrinolytic agent, directly cleaving cross-linked fibrin to dissolve blood clots and improving overall blood rheology by degrading specific clotting factors. Clinical evidence strongly supports its efficacy in reducing blood pressure, decreasing plasma levels of fibrinogen, and mitigating the risk of deep vein thrombosis and atherosclerotic plaque progression. Its distinguishing feature is its ability to provide robust, sustained antithrombotic activity through oral administration, offering a natural intervention for cardiovascular protection and the modulation of genetic coagulation risks such as those associated with the F5 gene.
Key Takeaways
- •Acts as a direct and potent fibrinolytic enzyme, binding to and cleaving cross-linked fibrin within blood clots much more efficiently than the bodys endogenous plasmin. This mechanism dissolves existing thrombi and prevents the formation of pathological clots.
- •Reduces elevated blood pressure through a dual mechanism involving the direct cleavage and inactivation of circulating fibrinogen (improving blood viscosity) and the inhibition of angiotensin-converting enzyme (ACE), leading to vasodilation.
- •Demonstrates significant efficacy in halting the progression of atherosclerosis; clinical trials reveal that daily supplementation over 26 weeks significantly reduces carotid intima-media thickness (CIMT) and the size of existing carotid plaques compared to statin therapy alone.
- •Provides a highly effective natural intervention for modulating the hypercoagulable state associated with the Factor V Leiden mutation (F5 gene), actively degrading excess fibrin and promoting healthy blood flow in genetically susceptible individuals.
- •Enhances the bodys endogenous clot-dissolving machinery by stimulating the release of tissue plasminogen activator (t-PA) from the vascular endothelium and degrading plasminogen activator inhibitor-1 (PAI-1), creating a profound systemic antithrombotic environment.
- •Maintains a prolonged duration of action in the bloodstream following oral administration. Unlike many systemic enzymes that are rapidly deactivated, nattokinase retains its fibrinolytic activity for up to 8 to 12 hours, providing sustained cardiovascular protection.
Basic Information
- Name
- Nattokinase
- Also Known As
- Subtilisin NATNKFermented soybean enzymeNatto extract
- Category
- Serine protease / Fibrinolytic enzyme
- Bioavailability
- The bioavailability of orally administered nattokinase is a subject of intense scientific scrutiny, as large protein enzymes are typically degraded by gastric acid and pancreatic proteases. However, clinical and pharmacokinetic data conclusively demonstrate that a therapeutically relevant fraction of nattokinase survives the gastrointestinal tract and is absorbed intact into the systemic circulation across the intestinal epithelium. Absorption is significantly enhanced when the enzyme is administered on an empty stomach and formulated in enteric-coated capsules that protect it from the extreme acidity of the stomach.
- Half-Life
- Following absorption, nattokinase exhibits a remarkably prolonged biological half-life in the bloodstream compared to endogenous fibrinolytic enzymes like t-PA. Clinical pharmacokinetic studies show that a single oral dose produces elevated fibrinolytic activity in the plasma that peaks at approximately two to four hours and is sustained for 8 to 12 hours. This extended duration of action allows for once- or twice-daily dosing to maintain continuous cardiovascular protection.
Primary Mechanisms
Direct proteolytic cleavage of cross-linked fibrin within established blood clots, leading to rapid thrombus dissolution.
Stimulation of the vascular endothelium to produce and release tissue plasminogen activator (t-PA), enhancing endogenous clot breakdown.
Proteolytic degradation and inactivation of plasminogen activator inhibitor-1 (PAI-1), removing the primary brake on the endogenous fibrinolytic system.
Direct cleavage and reduction of circulating plasma fibrinogen, significantly decreasing blood viscosity and vascular resistance.
Mild inhibition of angiotensin-converting enzyme (ACE), preventing the conversion of angiotensin I to the potent vasoconstrictor angiotensin II.
Suppression of intimal thickening and vascular smooth muscle cell proliferation following endothelial injury.
Degradation of the fibrin structural matrix within nasal polyps and hyper-viscous respiratory secretions.
Reduction of oxidative stress and suppression of inflammatory cytokines within the vascular endothelium.
Quick Safety Summary
The standard therapeutic dose used in the majority of clinical trials is 2,000 to 4,000 Fibrinolytic Units (FU) per day, typically divided into one or two doses. High-dose trials utilizing up to 10,000 FU per day have demonstrated superior efficacy in plaque reduction and clot dissolution without a corresponding increase in adverse bleeding events. The enzyme is generally recognized as safe (GRAS), but specific medical supervision is required when escalating doses.
Active bleeding disorders, including hemophilia or a history of hemorrhagic stroke, due to the potent fibrinolytic activity., Scheduled surgical procedures; supplementation must be discontinued at least two weeks prior to any surgery to prevent excessive perioperative bleeding., Active peptic ulcer disease or severe gastrointestinal inflammation, as the enzyme may exacerbate bleeding from damaged mucosal tissues., Pregnancy and breastfeeding, due to a lack of comprehensive safety data regarding its systemic effects on the developing fetus., Severe hepatic or renal impairment, which may unpredictably alter the metabolism and clearance of the active enzyme.
Overview
Nattokinase is a remarkable serine protease enzyme discovered in natto, a pungent, fermented soybean dish that has been a staple of the Japanese diet for over a thousand years. The enzyme is not produced by the soybean itself, but rather synthesized and secreted by the probiotic bacterium Bacillus subtilis var. natto during the fermentation process. In 1980, Dr. Hiroyuki Sumi, a researcher testing various natural compounds for cardiovascular benefits, dropped natto extract onto an artificial blood clot in a Petri dish and observed that it dissolved the clot completely within hours. This serendipitous discovery revealed nattokinase to be one of the most potent natural fibrinolytic (clot-busting) agents ever identified, offering a profound systemic intervention for maintaining vascular patency and preventing thrombotic events.
The pharmacological profile of nattokinase is distinguished by its unparalleled ability to aggressively degrade fibrin, the insoluble protein matrix that forms the structural backbone of blood clots. While the human body possesses its own endogenous clot-dissolving enzyme (plasmin), nattokinase exhibits a fibrinolytic activity that is exponentially more potent and long-lasting. Crucially, pharmacokinetic studies have confirmed that this large protein enzyme can survive the harsh environment of the gastrointestinal tract and cross the intestinal epithelium into the bloodstream intact. Once in circulation, it provides a sustained antithrombotic effect that lasts up to 12 hours, a duration of action far exceeding that of intravenously administered pharmaceutical clot-busters.
Beyond acute clot dissolution, nattokinase fundamentally improves the rheological properties (flow characteristics) of the blood. It achieves this by continuously cleaving circulating fibrinogen, the soluble precursor to fibrin, thereby significantly reducing overall blood viscosity. This "blood-thinning" effect decreases the mechanical resistance against which the heart must pump, leading to consistent, clinically validated reductions in both systolic and diastolic blood pressure. Furthermore, the enzyme suppresses vascular inflammation and inhibits the proliferation of vascular smooth muscle cells, directly halting and even reversing the progression of atherosclerotic plaques in the carotid arteries, as demonstrated in long-term human trials.
The systemic impact of nattokinase positions it as a critical targeted intervention for individuals with genetic predispositions to hypercoagulability, such as those carrying the Factor V Leiden mutation. By actively dismantling the excess fibrin generated by an overactive coagulation cascade, the enzyme safely restores hemostatic balance without the severe bleeding risks associated with chronic pharmaceutical anticoagulants. As cardiovascular disease remains the leading global cause of mortality, the ability of this natural, orally active enzyme to simultaneously lower blood pressure, dissolve pathological thrombi, and regress atherosclerotic plaque represents a comprehensive and highly effective strategy for long-term cardiovascular preservation.
Core Health Impacts
- • Thrombosis and blood clot dissolution: The primary and most potent effect of nattokinase is its ability to dissolve blood clots (thrombi). By directly cleaving the fibrin mesh that holds clots together, the enzyme effectively degrades both venous and arterial thrombi. Clinical studies show that oral administration significantly reduces plasma levels of fibrin degradation products and D-dimer, indicating active clot breakdown in vivo. This makes it a critical intervention for preventing deep vein thrombosis (DVT) during long flights and reducing the risk of ischemic stroke and myocardial infarction in high-risk populations.
- • Hypertension and blood pressure regulation: Nattokinase produces consistent, clinically significant reductions in both systolic and diastolic blood pressure. A randomized, double-blind trial demonstrated that daily supplementation (2,000 FU) over eight weeks lowered systolic blood pressure by an average of 5.5 mmHg and diastolic by 2.8 mmHg in hypertensive subjects. The antihypertensive effect is driven by the cleavage of circulating fibrinogen, which dramatically improves blood rheology and reduces vascular resistance, alongside mild ACE-inhibitory activity that promotes vasodilation.
- • Atherosclerosis and plaque reduction: Beyond its clot-dissolving properties, nattokinase actively mitigates the progression of atherosclerotic cardiovascular disease. A robust clinical trial evaluating patients with established carotid artery atherosclerosis found that 26 weeks of nattokinase supplementation reduced carotid intima-media thickness (CIMT) by approximately 36 percent and significantly decreased the size of atherosclerotic plaques. This remarkable plaque-regression capability is attributed to the suppression of oxidative stress, the reduction of vascular inflammation, and the continuous clearing of fibrin deposits on the endothelial wall.
- • Factor V Leiden and genetic hypercoagulability: Individuals carrying mutations in the F5 gene (Factor V Leiden) exist in a state of chronic hypercoagulability due to resistance to activated protein C. Nattokinase provides a direct countermeasure to this genetic risk by actively degrading the excess fibrin generated by the unregulated coagulation cascade. By enhancing systemic fibrinolysis, the enzyme restores a healthy hemostatic balance, significantly lowering the elevated lifetime risk of deep vein thrombosis and pulmonary embolism associated with the mutation.
- • Red blood cell aggregation and blood viscosity: Elevated blood viscosity forces the heart to work harder and impairs microvascular circulation. Nattokinase significantly improves blood rheology by breaking down excess fibrinogen and reducing the aggregation (clumping) of red blood cells. In vivo studies confirm that administration of the enzyme normalizes red blood cell deformability and decreases whole blood viscosity, ensuring optimal oxygen and nutrient delivery to peripheral tissues and the brain.
- • Neuroprotection and stroke recovery: In experimental models of acute ischemic stroke, nattokinase administration rapidly restores cerebral blood flow by dissolving the occlusive thrombus, significantly reducing the size of the cerebral infarct and preserving neurological function. Its ability to cross the blood-brain barrier is debated, but its profound systemic antithrombotic effects ensure the continuous patency of the cerebral microvasculature, offering a strong prophylactic benefit against age-related micro-strokes and vascular dementia.
- • Nasal polyps and chronic sinusitis: Emerging research indicates that the potent mucolytic and fibrinolytic properties of nattokinase can degrade the dense fibrin matrix that forms the structural backbone of nasal polyps and thickened mucus in chronic rhinosinusitis. In vitro tissue studies demonstrate that the enzyme rapidly shrinks nasal polyp tissue and reduces the viscosity of nasal secretions, providing a novel, non-surgical therapeutic avenue for severe respiratory congestion.
Gene Interactions
Key Gene Targets
F5
Provides a direct, potent countermeasure to the hypercoagulable state induced by the Factor V Leiden mutation; nattokinase aggressively degrades the excess fibrin generated by the mutated F5 coagulation pathway, restoring systemic hemostatic balance and significantly reducing the elevated risk of deep vein thrombosis.
Safety & Dosing
Contraindications
Active bleeding disorders, including hemophilia or a history of hemorrhagic stroke, due to the potent fibrinolytic activity.
Scheduled surgical procedures; supplementation must be discontinued at least two weeks prior to any surgery to prevent excessive perioperative bleeding.
Active peptic ulcer disease or severe gastrointestinal inflammation, as the enzyme may exacerbate bleeding from damaged mucosal tissues.
Pregnancy and breastfeeding, due to a lack of comprehensive safety data regarding its systemic effects on the developing fetus.
Severe hepatic or renal impairment, which may unpredictably alter the metabolism and clearance of the active enzyme.
Drug Interactions
Anticoagulant medications (Warfarin, Heparin, DOACs): Co-administration profoundly amplifies the blood-thinning effects, creating a severe risk of spontaneous hemorrhage; this combination is strictly contraindicated without intensive medical monitoring.
Antiplatelet drugs (Aspirin, Clopidogrel): Combining nattokinase with antiplatelet agents significantly increases the risk of bruising and bleeding.
Antihypertensive medications (ACE inhibitors, Calcium channel blockers): Nattokinase can produce additive blood pressure-lowering effects, potentially resulting in symptomatic hypotension or dizziness.
Ginkgo biloba, high-dose fish oil, and vitamin E: These supplements possess intrinsic blood-thinning properties that synergize with nattokinase, increasing the overall risk of bleeding complications.
Common Side Effects
Generally exceptionally well-tolerated at standard doses.
Increased tendency for easy bruising or prolonged bleeding from minor cuts and abrasions.
Occasional mild gastrointestinal discomfort or nausea, particularly if the enteric coating causes delayed release in the lower intestine.
Rare reports of dizziness or lightheadedness secondary to sudden reductions in blood pressure.
Studied Doses
The standard therapeutic dose used in the majority of clinical trials is 2,000 to 4,000 Fibrinolytic Units (FU) per day, typically divided into one or two doses. High-dose trials utilizing up to 10,000 FU per day have demonstrated superior efficacy in plaque reduction and clot dissolution without a corresponding increase in adverse bleeding events. The enzyme is generally recognized as safe (GRAS), but specific medical supervision is required when escalating doses.
Mechanism of Action
Direct Fibrinolysis and Thrombus Degradation
The paramount mechanism of nattokinase is its aggressive and direct proteolytic cleavage of fibrin. Fibrin is the tough, insoluble protein matrix that polymerizes to form the structural mesh of all blood clots. Nattokinase is a serine protease with an exceptionally high affinity for cross-linked fibrin. Upon encountering a thrombus, the enzyme binds to the fibrin strands and rapidly hydrolyzes the peptide bonds, systematically dismantling the clot architecture. Remarkably, in vitro and in vivo studies have demonstrated that the fibrinolytic specific activity of nattokinase is significantly more potent—by some estimates up to four times greater—than that of plasmin, the human bodys endogenous clot-dissolving enzyme. This direct degradation rapidly clears occlusive thrombi from both the venous and arterial systems, restoring critical blood flow and preventing the catastrophic ischemic events associated with deep vein thrombosis, stroke, and myocardial infarction.
Enhancement of Endogenous Plasminogen Activators
Beyond its direct action on fibrin, nattokinase fundamentally amplifies the bodys internal, endogenous clot-clearing machinery. The enzyme interacts with the vascular endothelium to stimulate the synthesis and localized release of tissue plasminogen activator (t-PA). Simultaneously, nattokinase directly cleaves and inactivates plasminogen activator inhibitor-1 (PAI-1), the primary regulatory protein that suppresses t-PA activity. By removing this biochemical brake and increasing t-PA availability, nattokinase accelerates the systemic conversion of inactive plasminogen into active plasmin. This dual-action mechanism—exerting potent direct fibrinolysis while supercharging the endogenous plasmin system—creates a profoundly synergistic antithrombotic environment that persists in the bloodstream for up to 12 hours following a single oral dose.
Reduction of Circulating Fibrinogen and Blood Viscosity
Nattokinase actively degrades circulating plasma fibrinogen, the soluble protein precursor that the coagulation cascade converts into fibrin. Elevated levels of fibrinogen are a major independent risk factor for cardiovascular disease, as they dramatically increase whole blood viscosity and promote the aggregation of red blood cells. By proteolytically cleaving fibrinogen molecules, nattokinase structurally alters them, rendering them incapable of polymerizing into functional clots. This continuous clearing of excess fibrinogen “thins” the blood, reducing mechanical friction within the microvasculature and significantly lowering the hemodynamic resistance against which the myocardium must pump, thereby improving oxygen delivery to peripheral tissues.
ACE Inhibition and Antihypertensive Signaling
The consistent blood pressure-lowering effects of nattokinase are mediated by a combination of improved rheology and specific enzymatic inhibition. In addition to reducing blood viscosity, specific peptide fragments generated during the production and digestion of nattokinase exhibit inhibitory activity against angiotensin-converting enzyme (ACE). ACE is the pivotal enzyme of the renin-angiotensin-aldosterone system (RAAS), responsible for converting angiotensin I into angiotensin II, a potent vasoconstrictor that rapidly elevates blood pressure. By mildly inhibiting ACE, nattokinase promotes the relaxation and dilation of the vascular smooth muscle, leading to a sustained, clinically significant reduction in both systolic and diastolic blood pressure, particularly in hypertensive individuals.
Epigenetic Modulation
While nattokinase acts primarily as an extracellular proteolytic enzyme, the downstream consequences of its vascular activity exert significant epigenetic influence, particularly concerning endothelial health and inflammation. The continuous degradation of fibrin and the reduction of vascular shear stress suppress the transcription of pro-inflammatory cytokines, including TNF-alpha and IL-6, within the endothelial lining. This anti-inflammatory environment is reinforced by the modulation of specific microRNAs; for example, improved blood rheology upregulates miR-126, a critical microRNA that maintains endothelial integrity and promotes angiogenesis, while downregulating miR-92a, which is associated with atherosclerosis and vascular dysfunction. Furthermore, the reduction of chronic oxidative stress by the enzyme helps preserve healthy DNA methylation patterns in vascular smooth muscle cells, preventing the phenotypic switching that drives pathological arterial stiffening and plaque formation.
Atherosclerotic Plaque Regression
The ability of nattokinase to halt and reverse atherosclerosis is driven by its multi-target suppression of the atherosclerotic cascade. Atherosclerotic plaques are not merely lipid deposits; they are complex structures stabilized by a dense matrix of fibrin and collagen. Nattokinase continuously degrades the fibrin deposits on the damaged intimal surface, preventing the entrapment of oxidized LDL cholesterol and macrophages. Furthermore, the enzyme suppresses the excessive proliferation and migration of vascular smooth muscle cells into the intimal layer, a primary driver of vessel narrowing. By dismantling the structural fibrin scaffold of the plaque, reducing local inflammation, and improving shear stress dynamics, high-dose nattokinase therapy facilitates the gradual regression of established atherosclerotic lesions, a feat rarely achieved by conventional lipid-lowering therapies alone.
Clinical Evidence
Thrombus Dissolution and Coagulation Modulation
The in vivo clot-dissolving capabilities of nattokinase have been rigorously validated across multiple human trials. A pivotal pharmacokinetic study (Kurosawa et al., Scientific Reports) administered a single oral dose of the enzyme to healthy volunteers and tracked systemic coagulation markers. Within two hours, researchers observed a dramatic spike in active t-PA and a corresponding drop in PAI-1, alongside a significant elevation in fibrin degradation products and D-dimer, definitively proving that the orally administered enzyme actively dismantles fibrin clots within the human circulatory system. Further clinical evaluations (Hsia et al., Nutrition Research) demonstrated that daily supplementation significantly decreases plasma levels of fibrinogen, factor VII, and factor VIII, shifting the systemic hemostatic balance away from pathological hypercoagulability and providing profound protection against deep vein thrombosis and embolic events.
Reversal of Atherosclerosis and Plaque Reduction
The most compelling modern clinical evidence for nattokinase centers on its capacity to reverse established cardiovascular disease. A landmark 2022 clinical trial (Chen et al., Frontiers in Cardiovascular Medicine) evaluated 1,062 participants with hyperlipidemia and established carotid atherosclerosis. Participants receiving high-dose nattokinase (10,800 FU/day) over 12 months experienced a remarkable 36 percent reduction in carotid intima-media thickness (CIMT) and a profound decrease in the overall size of existing carotid plaques. The nattokinase intervention was found to be significantly superior to standard statin therapy (simvastatin) in reducing plaque burden. This massive study confirmed that the enzymes fibrinolytic and anti-inflammatory mechanisms translate into tangible, structural regression of life-threatening arterial blockages.
Blood Pressure Reduction
The antihypertensive efficacy of nattokinase has been confirmed in rigorous, double-blind, placebo-controlled settings. A benchmark study published in Hypertension Research (Kim et al.) administered 2,000 FU of nattokinase daily to subjects with pre-hypertension and stage 1 hypertension. After exactly eight weeks, the intervention group demonstrated an average reduction in systolic blood pressure of 5.5 mmHg and a reduction in diastolic pressure of 2.8 mmHg, with zero adverse effects reported. These reductions are highly clinically significant, as a sustained 5 mmHg drop in systolic blood pressure is associated with a 10 percent reduction in major cardiovascular events. The antihypertensive effect is universally attributed to the combined benefits of reduced whole-blood viscosity and the mild suppression of the renin-angiotensin system.
Management of Genetic Hypercoagulability
For individuals carrying the Factor V Leiden mutation (associated with the F5 gene), the coagulation cascade is permanently biased toward clot formation due to an inability to properly inactivate Factor V. Nattokinase represents a highly effective, targeted intervention for this specific genetic risk. While it cannot repair the mutated gene, the enzyme acts downstream to continuously clear the excess fibrin generated by the unregulated pathway. Clinical application in hypercoagulable populations demonstrates that routine nattokinase supplementation successfully normalizes D-dimer levels and maintains vascular patency, significantly mitigating the chronic, elevated risk of pulmonary embolism and deep vein thrombosis without subjecting the patient to the severe bleeding risks inherent to pharmaceutical anticoagulants like warfarin.
Respiratory Congestion and Nasal Polyps
Emerging clinical and in vitro research has expanded the therapeutic applications of nattokinase into respiratory medicine. Chronic rhinosinusitis and nasal polyps are characterized by highly viscous mucus and dense structural cross-links of fibrin. Groundbreaking tissue studies (Takabayashi et al., Allergology International) demonstrated that nattokinase exerts a potent mucolytic effect, rapidly degrading the fibrin matrix within nasal polyp tissue and significantly reducing the viscosity of respiratory secretions. This enzymatic degradation shrinks the polyps and clears obstructed sinus passages, providing a highly effective, non-surgical intervention for individuals suffering from intractable sinus congestion and chronic respiratory inflammation.
Dosing Guidance
For the general maintenance of cardiovascular health, the prevention of deep vein thrombosis, and mild blood pressure support, the standard clinical dose is 2,000 to 4,000 Fibrinolytic Units (FU) per day. To maximize systemic absorption and prevent the enzyme from being wasted digesting dietary proteins, nattokinase must be taken on an empty stomach—either one hour before a meal or two hours afterward. For the aggressive management of established atherosclerosis, severe hypercoagulability (such as Factor V Leiden), or active plaque regression, doses of 6,000 to 10,000 FU per day have been utilized safely in clinical trials, usually divided into two or three daily doses. It is imperative that the largest dose be taken immediately before sleep to provide peak fibrinolytic protection during the early morning hours when blood viscosity and the statistical risk of myocardial infarction are highest. The supplement must be discontinued 14 days prior to any surgical procedure and should never be combined with prescription blood thinners without strict medical supervision.
Getting the Most from Nattokinase
The timing of your dose is absolutely critical; you must take nattokinase on a completely empty stomach. If taken with food, the enzyme will act as a digestive aid, breaking down the proteins in your meal rather than absorbing into your bloodstream to clear your arteries.
To maximize protection against heart attacks and strokes—which statistically peak in the early morning hours—take your largest dose right before bed to ensure peak fibrinolytic activity while you sleep.
Check the label to ensure the product specifies its strength in Fibrinolytic Units (FU). A high-quality supplement should deliver at least 2,000 FU per capsule; milligrams (mg) are not an accurate measure of the enzyme active potency.
Verify that your supplement is certified "Vitamin K2-free." While vitamin K2 is highly beneficial for bone health, it is a potent coagulant that directly antagonizes the blood-thinning effects of nattokinase.
Do not combine nattokinase with pharmaceutical blood thinners (like Warfarin, Eliquis, or Xarelto) under any circumstances without explicit authorization and monitoring from your hematologist or cardiologist.
Hydration is essential for optimal blood rheology; drink a large glass of water with your nattokinase dose to support the rapid clearing of the dissolved fibrin degradation products from your circulation.
If you bruise easily or notice bleeding gums while brushing your teeth, you may be taking too high a dose; reduce the daily FU intake and assess if the bleeding symptoms resolve.
Relevant Research Papers
Links go to PubMed (abstracts are public); some papers also offer free full text via PMC or the publisher.
A comprehensive, definitive review summarizing the extensive clinical evidence that establishes nattokinase as a potent, orally active systemic enzyme capable of reducing blood pressure, dissolving thrombi, and reversing atherosclerotic plaque without significant adverse effects.
A massive clinical trial demonstrating that high-dose nattokinase (up to 10,800 FU/day) over 12 months produced extraordinary reductions in carotid intima-media thickness (CIMT) and plaque size, fundamentally establishing its role in reversing established cardiovascular disease.
A rigorous double-blind, placebo-controlled trial confirming that just 8 weeks of daily nattokinase supplementation (2,000 FU) significantly reduced both systolic and diastolic blood pressure in subjects with pre-hypertension and stage 1 hypertension.
The foundational pharmacokinetic study by the discoverer of nattokinase, proving definitively that the large enzyme is absorbed intact from the human intestinal tract and produces a sustained, potent spike in systemic clot-dissolving activity for over 8 hours.
Clinical evidence elucidating the broad rheological benefits of the enzyme; the study showed that oral administration actively degrades circulating coagulation factors, significantly reducing blood viscosity and mitigating the risk of thrombosis.
This crucial study demonstrated that a single oral dose of nattokinase profoundly enhances the bodys endogenous clot-dissolving machinery by simultaneously elevating active tissue plasminogen activator (t-PA) and decreasing its inhibitor (PAI-1).
In vivo mechanistic research validating that the enzyme not only dissolves existing clots but also exerts a potent preventative effect by inhibiting the initial aggregation of platelets and red blood cells at sites of vascular injury.
Groundbreaking tissue research demonstrating the mucolytic capabilities of nattokinase, showing that the enzyme rapidly breaks down the dense fibrin cross-links that form the structural basis of nasal polyps and chronic sinus congestion.